血源性生物标志物预测肝硬化预后研究进展  

Research Progress of Blood-Derived Biomarkers Predicting Prognosis of Liver Cirrhosis

作　　者：胡晓丽 文雅冰 孙金山[2] 

机构地区：[1]新疆医科大学研究生院,新疆 乌鲁木齐 [2]新疆军区总医院消化科,新疆 乌鲁木齐

出　　处：《临床医学进展》2023年第12期19716-19724,共9页Advances in Clinical Medicine

摘　　要：肝硬化(Liver Cirrhosis, LC)作为大多数慢性肝病(Chronic Liver Disease, CLD)的终末期,其死亡率较高,因此评估LC患者的预后并提供精确管理对降低死亡风险至关重要。目前已有多种评分系统用于评估LC患者的预后,但因其侵入性或主观性影响了评估的准确度。近年来,研究人员发现,血源性生物标志物对LC患者的预后有一定的预测价值。因其标本采集简单、无创并且可重复,其有望成为预测LC预后的可靠指标。本文主要对血源性生物标志物在预测LC预后功能中的作用做一综述。As the end stage of most chronic liver diseases (LC), cirrhosis has a high mortality rate, so assessing the prognosis of patients with chronic liver disease (CLD) and providing precise management is es-sential to reduce the risk of death. A variety of scoring systems have been used to evaluate the prognosis of patients with LC, but their invasive or subjective nature has affected the accuracy of the assessment. In recent years, researchers have found that blood-derived biomarkers have some predictive value for the prognosis of LC patients. Because of its simple specimen collection, non-invasive and repeatable, it is expected to be a reliable indicator for predicting the prognosis of LC. This review focuses on the role of blood-derived biomarkers in predicting the prognosis of LC.

关 键 词：肝硬化 预测 血源性生物标志物 

分 类 号：R73[医药卫生—肿瘤]